BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer-Reference-Cited by-同舟云学术

BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer

Published:2017-12 Issue:12 Volume:21 Page:3398-3405
ISSN:2211-1247
Container-title:Cell Reports
language:en
Short-container-title:Cell Reports

Author:

Karakashev Sergey,Zhu Hengrui,Yokoyama Yuhki,Zhao Bo,Fatkhutdinov Nail,Kossenkov Andrew V.,Wilson Andrew J.,Simpkins Fiona,Speicher David,Khabele Dineo,Bitler Benjamin G.,Zhang Rugang

Funder

NIH/National Cancer Institute

U.S. Department of Defense

Ovarian Cancer Research Fund

Cancer Center Support Grant

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology

Reference24 articles.

1. HMGB2 orchestrates the chromatin landscape of senescence-associated secretory phenotype gene loci;Aird;J. Cell Biol.,2016

2. The history and future of targeting cyclin-dependent kinases in cancer therapy;Asghar;Nat. Rev. Drug Discov.,2015

3. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer;Bowtell;Nat. Rev. Cancer,2015

4. AmiGO: online access to ontology and annotation data;Carbon;Bioinformatics,2009

5. PARP inhibitors enhance replication stress and cause mitotic catastrophe in MYCN-dependent neuroblastoma;Colicchia;Oncogene,2017

Cited by 137 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PARP inhibitor resistance mechanisms and PARP inhibitor derived imaging probes;Expert Review of Anticancer Therapy;2024-09-03

2. Circulating tumor cells: from new biological insights to clinical practice;Signal Transduction and Targeted Therapy;2024-09-02

3. Combined strategies with PARP inhibitors for the treatment of BRCA wide type cancer;Frontiers in Oncology;2024-08-02

4. Poly (ADP-ribose) polymerase inhibitor therapy and mechanisms of resistance in epithelial ovarian cancer;Frontiers in Oncology;2024-07-29

5. Repression of PRMT activities sensitize homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment;2024-07-17